UK-based Peak Analysis and Automation has developed an autonomous primary antibody screening robot for early stage development of potential new treatments for central nervous system and immunology conditions. The robot, which is being used in the UK to screen antibodies against a range of infectious agents, can be programmed with different types of antibodies, including those that are known or suspected to cause neurological diseases.
UK-based Peak Analysis and Automation has developed an autonomous primary antibody screening robot for early stage development of potential new treatments for central nervous system and immunology conditions. Designed for easy modification and customisation of its operations, the machine allows for the simultaneous screening of billions of antibody producing B cells, reducing the time taken to develop therapies for numerous disorders.